Preventing Gastrointestinal Disturbance in Patients After Longitudinal Laparotomy. (ORE001PIIPOI)
A Multi-center, Randomized, Double Blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy of ORE-001 in Preventing Gastrointestinal Disturbance/ Intolerance in Patients After Longitudinal Laparotomy
Sponsor: Orexa BV
This PHASE2 trial investigates Ileus Postoperative and is currently actively recruiting participants. Orexa BV leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Aug 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Orexa BV
- QPS Holdings LLC
For direct contact, visit the study record on ClinicalTrials.gov .